Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 125, Issue 9, Pages 3347-3355Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI80007
Keywords
-
Categories
Funding
- NIH [CA127923, AI043477]
- German Research Foundation
- Irvington-Cancer research Institute
Ask authors/readers for more resources
Cancer development and its response to therapy are strongly influenced by innate and adaptive immunity, which either promote or attenuate tumorigenesis and can have opposing effects on therapeutic outcome. Chronic inflammation promotes tumor development, progression, and metastatic dissemination, as well as treatment resistance. However, cancer development and malignant progression are also associated with accumulation of genetic alterations and loss of normal regulatory processes, which cause expression of tumor-specific antigens and tumor-associated antigens (TAAs) that can activate antitumor immune responses. Although signals that trigger acute inflammatory reactions often stimulate dendritic cell maturation and antigen presentation, chronic inflammation can be immunosuppressive. This antagonism between inflammation and immunity also affects the outcome of cancer treatment and needs to be considered when designing new therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available